Case ReportBoston Ocular Surface Prosthesis for Persistent Epitheliopathy After Treatment of Conjunctival MelanomaGrover, Surbhi MD, PhD; Jacobs, Deborah S MD; Colby, Kathryn A MD, PhDAuthor Information From the *Harvard Medical School, Boston, MA; and the †Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, MA. Received for publication February 5, 2009; revision received June 4, 2009; accepted June 14, 2009. Dr. Jacobs is a salaried employee of the Boston Foundation for Sight, a 501(c)3 nonprofit. She has no proprietary or financial interest in the Boston Ocular Surface Prosthesis. Reprints: Kathryn A. Colby, MD, PhD, Massachusetts Eye and Ear Infirmary, 243 Charles Street, Boston, MA 02114 (e-mail: email@example.com). Cornea: April 2010 - Volume 29 - Issue 4 - p 459-461 doi: 10.1097/ICO.0b013e3181b55b40 Buy Metrics Abstract Purpose: To report two cases of persistent epitheliopathy after treatment of conjunctival melanoma and review management options for this condition. Methods: Case report and literature review. Results: Persistent epitheliopathy, presumably resulting from limbal stem cell deficiency, is an uncommon complication of treatment of conjunctival malignant melanoma with surgical excision, cryotherapy, and mitomycin C. The Boston Ocular Surface Prosthesis was successful in improving vision, comfort, and epithelial status in our patients. Conclusion: Persistent epitheliopathy is a rare complication of treatment of conjunctival melanoma. The Boston Ocular Surface Prosthesis is a viable treatment option in this situation. Copyright © 2010 Wolters Kluwer Health, Inc. All rights reserved.